RxPT Announcements

MDH shares in this space, through GovDelivery bulletins and, as appropriate, via State Register announcements, information related to the Prescription Drug Price Transparency Act's implementation and opportunities for public feedback.

Stakeholders interested in receiving announcements on implementation of the act may subscribe to Prescription Drug Price Transparency updates.

Reporting on the first list of drugs of substantial public interest is now open 

August 1, 2024

Reporting is now open in the Rx Data Reporting Portal for the first list of Drugs of Substantial Public Interest. MDH sent notifications to entities registered in the Portal on 08/01/2024. Reports are due 60 days later, 09/30/2024. 

MDH releases the inaugural list of Drugs of Substantial Public Interest and updated reporting guidance

June 26, 2024

MDH released the inaugural list of Drugs of Substantial Public Interest—June 2024 [List of Drugs of Substantial Public Interest (Excel) and List Methodology for Drugs of Substantial Public Interest Reporting (PDF)] for new reporting under the Minnesota Prescription Drug Price Transparency Act. Additionally, MDH prepared reporting guidance and supporting materials, which are available on the RxPT For Reporting Entities page. Manufactures, pharmacies, wholesalers, and PBMs with a reporting obligation will be notified of the need to report no sooner than 30 days after this release, and they will have 60 days after the date of notification to report.

MDH releases 2024 Report to the Minnesota Legislature

May 20, 2024

MDH released the Minnesota Prescription Drug Transparency: 2024 Report to the Minnesota Legislature (PDF). It presents analysis of information reported to MDH through June 2023, provides a summary and timeline for the implementation of new work, and assesses the Act's progress toward statutory goals.

MDH invites comments on draft methodology for the inaugural list of drugs of substantial public interest

April 23, 2024

The Minnesota Department of Health (MDH) has released a draft methodology for the inaugural list of drugs of substantial public interest and is announcing a public comment period. MDH expects to subsequently release the final list in late spring. Stakeholders may submit comments by emailing health.Rx@state.mn.us or through submission of the Public Input on Prescription Drug Price Transparency in Minnesota form by 4 p.m. CT on May 9, 2024.

Register to report Rx data at MDH

December 4, 2023

New requirements to register with MDH's online reporting system under the Prescription Drug Price Transparency Act (MS 62J.84) goes into effect January 1, 2024, and will apply to all manufactures, Pharmacy Benefit Managers (PBMs), pharmacies, and wholesalers licensed in Minnesota. Some manufacturers may already be registered to report on new and price growth drugs. 

Registration is newly opened to wholesalers, pharmacies, and PBMs. Reporting entities may access the online system to register at https://rxpt.health.mn.gov/. View MDH's Registration and Account Management Guide (PDF). 

Updated Draft Reporting Guidance Available for Public Comment

November 17, 2023

MDH has released updated draft reporting guidance (PDF) on Prescription Drug Price Transparency for public comment. Stakeholders may submit comment by emailing health.Rx@state.mn.us by 4:30 p.m. CT on Friday, December 8, 2023.

Updates include new reporting on Drugs of Substantial Public Interest and modified registration requirements under 62J.84 (Laws of Minnesota 2023, Chapter 70, Article 2, Sections 8-21, 43). Technical fixes to the original legislation were integrated into the Form and Manner guidance in August of 2023.

Comment Deadline:

Friday, December 8, 2023, at 4:30 p.m. CT

Please email written feedback to health.Rx@state.mn.us

Updated data

November 9, 2023

The Minnesota Department of Health (MDH) has released new data contained in online data dashboards and downloadable files for the Minnesota Prescription Drug Price Transparency initiative. Access the interactive dashboards and downloadable files.

MDH previews implementation timeline for expanded prescription drug price transparency reporting

October 16, 2023

MDH shared the implementation timeline for expanded prescription drug price transparency reporting on drugs of significant public interest and ways to stay connected.

Updated reporting guidance released

Update on August 1, 2023

MDH has released updated reporting guidance addressing technical fixes to existing manufacturer reporting.

Revised Form and Manner Aug 2023 (PDF)

Updates to Rx Price Transparency Reporting After the 2023 Legislative Session

Update on June 13, 2023

As a result of the Minnesota Legislature’s 2023 Session, there are several upcoming changes to Minnesota’s Prescription Drug Price Transparency reporting. The Minnesota Department of Health (MDH) recently announced an upcoming opportunity to provide comment on draft updated reporting requirements under the original Price Transparency legislation. See MDH’s full announcement here.

MDH publishes inaugural batch of prescription drug list prices and report

Update on February 21, 2023

The Minnesota Department of Health (MDH) has released its first legislative report, data dashboards, and downloadable files for the Minnesota Prescription Drug Price Transparency initiative. View the Rx Legislative report Feb 2023 (PDF) and access the interactive dashboards and downloadable files.